Health plans are lobbying the Trump administration to scrap a proposal dating from the final days of the Biden administration that would require Medicare and Medicaid to cover anti-obesity drugs, including GLP-1s, for weight loss. Why it matters: The final decision, expected in April, is an important barometer of which healthcare interests have President Trump's ear, since many providers, patients and drugmakers want Medicare to cover the products.
